posts tagged as Pharmaceuticals


6 Trends Pharma Should Follow: BDO Life Sciences Letter Explains

Changes to global tax laws, rising drug pricing pressures and uncertainty around healthcare reform are just a few developments the pharma industry is watching. In the Spring 2017 Life Sciences Letter, BDO explores these topics and more... read more


How Innovations and Payment Models Seek to Tie Drug Pricing to Patient Outcomes

In efforts to better tie payments to outcomes, healthcare industry stakeholders are exploring new innovations and pricing models to evaluate the cost and efficacy of drugs and establish new and better ways of tracking patient outcomes... read more


Healthcare Reform: Insights from Inside the Beltway

We recently hosted a breakfast panel, Healthcare Reform: Insights from Inside the Beltway, during the 2017 J.P. Morgan Healthcare Conference, featuring our senior fellow, Dr. Scott Gottlieb, and Dave Tamasi of Rasky Baerlein, along with... read more


By Venson Wallin | January 26, 2017

2 Compliance Takeaways from the 21st Century Cures Act

On Dec. 13, President Obama signed the 21st Century Cures Act (the Cures Act) into law, boosting healthcare research dollars, streamlining the Food and Drug Administration (FDA)’s drug and medical device approvals processes, and... read more


By William Bithoney | August 08, 2016

Compounding Pressures: Multiple influencers push for U.S. drug prices to be tied to value, outcomes

Despite criticism, drug prices are still rising. Besides the complex issues of development, regulation and competition, and the bevy of price variables such as insurance contracts and pharmacy benefit manager formularies, pricing has... read more


The Politics of Drug Pricing vs. Reality of Payer Control – Recorded Bloomberg Intelligence Webinar

New legislation and pilot programs are helping to change the tide when it comes to how drugs are priced in the U.S. read more


BDO Knows Healthcare Spring 2016 Newsletter

In the Spring 2016 edition of the BDO Knows Healthcare newsletter, we focus on the impact of changing reimbursements across the healthcare spectrum: on investors, providers and pharmaceutical companies. read more


Pharma Companies Resist Behavioral Health

With 61.5 million American adults suffering from a mental health disorder, the need for new psychiatric treatments is high. read more


By David Friend | February 11, 2016

As Drug Price Scrutiny Rises, Pressure Builds to Define Value

Drug pricing is one of today’s most hotly debated and deeply complex topics, influencing and being influenced by the healthcare and pharmaceutical industries’ paradigm shift from fee-for-service to value-based care and... read more


Commercial Reasonableness Analysis for an Increasingly Regulated Healthcare Environment

With all the effort that goes into increasingly complex healthcare transactions, the last thing decision-makers want is to be hit with regulatory sanctions once the agreement is signed. Healthcare transactions are increasingly vulnerable... read more